Objective-To measure plasma concentrations of noradrenaline and neuropeptide Y-like immunoreactivity in relation to cardiac function in patients with congestive heart failure. Design-Retrospective analysis ofplasma noradrenaline concentrations and neuropeptide Y-like immunoreactivity in the arterial and coronary circulations, in patients with a high or low ejection fraction (31-3% (1.3%) or 17*7% (1.1%) respectively) and in healthy volunteers.
Abstract
Objective-To measure plasma concentrations of noradrenaline and neuropeptide Y-like immunoreactivity in relation to cardiac function in patients with congestive heart failure. Design-Retrospective analysis ofplasma noradrenaline concentrations and neuropeptide Y-like immunoreactivity in the arterial and coronary circulations, in patients with a high or low ejection fraction (31-3% (1.3%) or 17*7% (1.1%) respectively) and in healthy volunteers.
Setting-Cardiology department of a university hospital. Patients-41 patients with congestive heart failure with various aetiologies. Ten healthy volunteers served as a reference group.
Main outcome measures-Concentrations of noradrenaline measured by high performance liquid chromatography and of neuropeptide Y-like inmunoreactivity measured by radioimmunoassay. Cardiac index, pulmonary capillary wedge pressure, pulmonary vascular resistance, and systemic vascular resistance were derived by catheterisation of the right heart. Ejection fraction was measured by radionuclide angiography, cineangiography, or M mode echocardiography. Results-There were pronounced and significant increases in circulating arterial concentrations of neuropeptide Y-like immunoreactivity and noradrenaline in both the high and low ejection fraction groups compared with the healthy subjects. In the patients myocardial release of neuropeptide Y-like immunoreactivity tended to be greater compared with normal subjects, but not significantly so. While normal subjects showed myocardial noradrenaline uptake, patients with congestive heart failure showed significant and progressive myocardial noradrenaline release. where FB = blood flow in the coronary sinus; F, = infusion rate; TB, TIb TM = temperature of blood, injectate, and mixture of blood and injectate, respectively; and k = a constant derived from the density and specific heat of saline solution and blood. Blood samples (10 ml) were obtained from the coronary sinus and the radial artery respectively for measurements of plasma concentrations of noradrenaline and neuropeptide Y-like immunoreactivity. Pressures, flow rates, and blood samples were obtained at least 30 minutes after completion of catherisation.
Plasma concentrations of neuropeptide Ylike immunoreactivity were measured by radioimmunoassay according to the method of Theodorsson-Norheim et al.2' The antiserum was raised in rabbits and showed no (0 1%) cross reactivity to structurally related peptides such as peptide YY or pancreatic polypeptide. The sensitivity of the method was around 10 pmol/I in a 0 5 ml plasma. Intra-assay coefficient of variation for concentrations below 50 pmol/l was 7%.21 Plasma noradrenaline concentration: was analysed by high performance liquid chromatography with electrochemical detection. 22 The sensitivity of noradrenaline assay was 0-1 nmol in 2 ml plasma. Intra-assay coefficient of variation for concentrations below 10 nmol/l was 5.6%.22
Derived variables were calculated by the following equations: cardiac index = cardiac output/body surface area; stroke volume index = cardiac index/heart rate; pulmonary vascular resistance = (mean pulmonary artery pressure-pulmonary artery wedge pressure)/ cardiac output x 80; systemic vascular resistance = (mean artery pressure-right atrial pressure)/cardiac output x 80; myocardial release of neuropeptide Y-like immunoreactivity and noradrenaline = (coronary sinus concentration-arterial concentration) x coronary sinus flow. Results Table 1 shows mean haemodynamic values and plasma concentrations of neuropeptide Y-like immunoreactivity and noradrenaline in patients with congestive heart failure. The low ejection fraction group had lower cardiac indices, with higher concentrations of noradrenaline in arterial and coronary sinus blood. Arterial noradrenaline concentration was raised in both groups compared with the normal reference group, and it was significantly higher in the patients with a low ejection fraction than in those with a high ejection fraction compared with normal controls (p < 0 05, p --0-24 < 0X001 respectively). However, such significance was not found for the myocardial release of neuropeptide Y-like immunoreactivity, although it tended to be increased in the low ejection fraction group (fig 1) . cardiac index than did concentrations of neuropeptide Y-like immunoreactivity. Because the pumping of the heart is reduced in congestive heart failure efferent sympathetic nerve activity in renal23 and muscular sympathetic nerves24 is exaggerated and plasma concentrations of noradrenaline are high.2527 Plasma concentrations of noradrenaline are associated not only with the severity, but also with the prognosis of congestive heart failure.2528 Venous concentrations of neuropeptide Y-like immunoreactivity are raised in patients with congestive heart failure of various aetiology.29 30 Our results accord with the idea that plasma concentrations of neuropeptide Y-like immunoreactivity are increased in patients with moderate to severe heart failure. Interestingly, plasma concentrations in forearm veins in patients in other studies ranged from 54 pmol/130 to over 100 pmol129 by the same assay, which is higher than the concentrations of neuropeptide Y-like immunoreactivity that we found. This may indicate that venoarterial difference and peripheral release of neuropeptide Y-like immunoreactivity may exist in the forearm in congestive heart failure, although no clear cut venoarterial concentration differences were seen in normal subjects in the forearm at rest or during exercise. '6 Moreover, the condition of most of our patients was stable with treatments such as diuretics, digoxin, angiotensin converting enzyme inhibitors, and fi adrenergic blocking agents. These factors may also contribute to a lower plasma concentration of neuropeptide Y-like immunoreactivity that we found in our patients.
We used a normal reference group from a previous study '7 
